COVID-19 Respiratory InfectionLIGHTNCT07610967
Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections
A study testing RD-X19 in people with COVID-19 Respiratory Infection and Influenza, run by David Moss at 1 site in United States.
Trial summary
The purpose of trial is to determine if daily usage of a photobiomodulation device will decrease the incidence of upper respiratory tract infections (URI) due to COVID, influenza or other viruses.The RD-X10 device is handheld, can be self-administered, and has been shown to be safe in invivo studies. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- COVID-19 Respiratory Infection, Influenza
- What is being tested?
- RD-X19
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 130 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Oct 2026to Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Active Duty and DoD Beneficiaries (i.e. former military, spouse, dependent child) aged 18 years and older who work in the Mike O'Callaghan Military Medical Center at Nellis Air Force Base.
Who cannot join
- Unable to comfortably insert RD-X19 into the mouth and keep in place for 5 minutes
- Plans for head, neck or mouth surgery during the study period
- Plans for major dental procedures (ie implants, wisdom teeth extraction etc) during the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Mike O'Callaghan Military Medical Center
Nellis Air Force Base, Nevada, 89191
Sandra Huffman, BS, 702-653-3583, Sandra.g.huffman.ctr@health.mil
M
About this study
The purpose of trial is to determine if daily usage of a photobiomodulation device will decrease the incidence of upper respiratory tract infections (URI) due to COVID, influenza or other viruses.The RD-X10 device is handheld, can be self-administered, and has been shown to be safe in invivo studies.
Read the detailed description
Methods: Subjects 18 years and older working at a DoD medical facility and VA medical facility will be randomized into Active Treatment (Emit Bio ) and sham (inactive device). Basic demographic information will be obtained. Subjects will use the device at home every other day for 5 minutes. Baseline viral upper respiratory PCR panel will be obtained to ensure pre-existing infections are not counted. At first sign of upper respiratory infection symptoms, subjects will contact research personnel and have viral respiratory PCR panel obtained. Research coordinators will also contact subjects every two weeks to ask if they are experiencing or have experienced any upper respiratory symptoms or if they have experienced any side effects of treatment. Subjects reporting any current symptoms or symptoms in the prior 2 weeks will have upper respiratory PCR panel obtained. Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess secondary outcomes including duration of symptoms, missed days of work, outpatient medical visits, ED visits, hospitalizations, medication prescriptions for respiratory illness and over the counter treatments.
Screening visit (Approx 30 min):
- Obtain and document signed Informed Consent document and HIPAA Authorization
- Verify subject eligibility based on inclusion/exclusion criteria (research coordinators may use the electronic medical record to verify inclusion/exclusion)
- Record all medications the subject is taking
- Collect demographic information to include phone number, email address, DoD ID, age, race, ethnicity, sex, whether they directly care for patients, what department they work in, any therapies regularly used to prevent URI (ie zinc, mouth washes, supplements), and immunocompromised state or medications that may suppress the immune system, weight (pounds), height (inches), and BMI
Randomization:
Subjects will be randomized using block randomization (blocks of 6) into one of two research treatment groups, with approximately 50 subjects in each arm for a total of 100 subjects. The study staff assigning subjects to their group will be unblinded to the groups, but patients, investigators, and study staff conducting screening and gathering data will be blinded. The unique study code will be assigned in sequential order beginning with 001.
Group 1: Active RD-X19 every other day for 3 months Group 2: Sham RD-X19 every other day for 3 months
Visit 1 (week 0) (may be same day as screening visit) (approx. 30 minutes):
- Subject will be given the RD-X19 device and shown how to use the device
- Subjects will be instructed to use the device for 5 minutes every other day
- Subject will be given "Instructions for Treatment" handout
- Obtain a baseline PCR panel using a nasal swab
Visits 2-7 (weeks 2-12) (approx. 30 min) can be performed virtually or in person
- Subjects will be asked if they have experienced any upper respiratory symptoms in the last 2 weeks, this may include cough, congestion, sore throat, fatigue, runny nose, sinus pain or pressure, fever (subjective or Temp >100 F), sneezing.
- Subjects experiencing any of the above symptoms will be tested for URI causing viruses using PCR based testing.
- Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess secondary outcomes including duration of symptoms, missed days of work, outpatient medical visits, ED visits, hospitalizations, medication prescriptions for respiratory illness and over the counter treatments. They will also be assessed daily using the WURSS 24 (Wisconsin Upper Respiratory Symptom Survey) daily symptom report until they report a score of 0 for question 1 (How sick do you feel today?)
- Subjects who have not experienced any URI symptoms will be assessed for adherence to RDX19 over the previous 2 weeks and encouraged to continue using the device. They will also be asked if they are experiencing any side effects of the treatment such as throat or mouth irritation, sores in the mouth or on the lips or any other perceived side effects.
- At the end of each study visit, subjects will be asked if the device was used as directed.
Visit 7
-During the subjects final visit, they will be given a questionnaire regarding usage of the device
Device will only be used for a single patient and should be returned to research staff at the end of the study for disposal.
- Conditions
- COVID-19 Respiratory Infection, Influenza
- Being tested
- RD-X19, RD-X19 Sham
- Medical subject headings
- Influenza, Human
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RD-X19Device
- Subject will be given the RD-X19 device and shown how to use the device
- Subjects will be instructed to use the device for 5 minutes every other day
- Subject will be given "Instructions for Treatment" handout
RD-X19 ShamDevice
- Subject will be given the sham RD-X19 device and shown how to use the device
- Subjects will be instructed to use the sham device for 5 minutes every other day
- Subject will be given "Instructions for Treatment" handout
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Active RD-X19 every other day for 3 months | Experimental | Not described Receives: Device: RD-X19 |
| Group 2: Sham RD-X19 every other day for 3 months | Sham comparator | Not described Receives: Device: RD-X19 Sham |
What is being measured
The primary outcome is the main question the study is designed to answer.
difference in PCR confirmed URI (any virus)
difference in PCR confirmed URI (any virus) between active and sham groups between treatment period
Measured: visit 2 (week 2), visit 3 (week 4), visit 4 (week 6), visit 5 (week 8), visit 6 (week 10), visit 7 (week 12)
Secondary outcomes (11)
duration of symptoms
Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess duration of symptoms (days)
Measured: upper respiratory infection duration, an average of 2 weeks
missed days of work
Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess missed days of work
Measured: upper respiratory infection duration, an average of 2 weeks
outpatient visits
Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess number of outpatient visits
Measured: upper respiratory infection duration, an average of 2 weeks
emergency department visits
Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess number of emergency department visits
Measured: upper respiratory infection duration, an average of 2 weeks
hospitalizations
Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess number of hospitalizations
Measured: upper respiratory infection duration, an average of 2 weeks
Wisconsin Upper Respiratory Symptom Survey (WURSS 24)
Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess daily symptom severity score using WURSS 24.
The WURSS 24 is an illness-specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infections. Subjects rate their symptoms and daily impairments using 0-7-point Likert scales. Minimum value is 0, maximum value is 154. Higher score means worse outcome.
Measured: upper respiratory infection duration, an average of 2 weeks
number and type of medication prescriptions for respiratory illness
Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess number and type medication prescriptions for respiratory illness. Example: 1 medication prescription, medication prescription=Tamiflu.
Measured: upper respiratory infection duration, an average of 2 weeks
number and type of over the counter treatments used
Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess number an d type of over the counter treatments used. Example: 1 OTC treatment used, OTC treatment=ibuprofen.
Measured: upper respiratory infection duration, an average of 2 weeks
differences in incidence of URI amongst different viruses from PCR panels
differences in incidence of URI amongst different viruses from PCR panels
Measured: through study duration, an average of 12 weeks
treatment side effects
treatment side effects
Measured: through study duration, an average of 12 weeks
adherence to daily use of RD-X19 device throughout study
adherence to daily use of RD-X19 device as reported to study staff at all visits (1-7)
Measured: through study duration, an average of 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 May 2026
- Study start1 Oct 2026
- Primary completionJun 2028 (estimated)
- Study completionJun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for COVID-19 Respiratory InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Group 1: Active RD-X19 every other day for 3 months Group 2: Sham RD-X19 every other day for 3 months
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 130 participants (estimated)
Sponsor and investigators
- Lead sponsor
- David Moss
- Sponsor type
- US federal agency
- Responsible party
- Sponsor-investigator, David Moss, Mike O'Callaghan Military Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07610967
- Sponsor's protocol ID
- MOFMC.2026.0032
- Acronym
- LIGHT
- Status last verified
- Oct 2026
- First submitted
- 14 May 2026
- Last updated
- 26 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Demographic and clinical data will be acquired from participants. All data will be de-identified prior to receipt by the repository, but the information needed to generate a global unique identifier for the NLM Data Archive (NDA) (clinicaltrials.gov) will be collected for each subject. Sufficient data from this project will be preserved to enable sharing via NDA data of sufficient quality to validate and replicate research findings described in the Aims. NLM requires data measured from human subjects to be shared using the NDA. Demographic data, clinical data, data collection tools and study protocols will be made available in the NDA.
Publications
Stasko N, Arwood L, Jandick N, Spragion D, Roberts RC, Setien M, Henson I, Annas A, Fulcher ML, Brotton M, Kummer L, Szaba F, Reagan M, Lanzer K, Cookenham T, Casey S, Kothapalli N, Hart T, Bradrick SS, Emerson D, Cockrell AS, Randell SH, Kocher JF. The pan-variant potential of light: 425 nm light inactivates SARS-CoV-2 variants of concern and non-cytotoxic doses reduce viral titers in human airway epithelial cells. mSphere. 2025 Jun 25;10(6):e0023025. doi: 10.1128/msphere.00230-25. Epub 2025 May 28.
PubMed 40434113Gibson S, Saunders R, Stasko N, Bickerstaff CB, Oakley J, Osterman M, Torres RT, Kish JK, Feinberg BA, Emerson D. Economic and clinical impact of a novel, light-based, at-home antiviral treatment on mild-to-moderate COVID-19. J Med Econ. 2022 Jan-Dec;25(1):503-514. doi: 10.1080/13696998.2022.2055370.
PubMed 35387539Stasko N, Cockrell AS, Kocher JF, Henson I, Emerson D, Wang Y, Smith JR, Henderson NH, Wood H, Bradrick SS, Jones T, Santander J, McNeil JG. A randomized, controlled, feasibility study of RD-X19 in subjects with mild-to-moderate COVID-19 in the outpatient setting. Clin Transl Sci. 2022 May;15(5):1291-1303. doi: 10.1111/cts.13249. Epub 2022 Feb 27.
PubMed 35137532Zupin L, Gratton R, Fontana F, Clemente L, Pascolo L, Ruscio M, Crovella S. Blue photobiomodulation LED therapy impacts SARS-CoV-2 by limiting its replication in Vero cells. J Biophotonics. 2021 Apr;14(4):e202000496. doi: 10.1002/jbio.202000496. Epub 2021 Mar 1.
PubMed 33619888Stasko N, Kocher JF, Annas A, Henson I, Seitz TS, Miller JM, Arwood L, Roberts RC, Womble TM, Keller EG, Emerson S, Bergmann M, Sheesley ANY, Strong RJ, Hurst BL, Emerson D, Tarbet EB, Bradrick SS, Cockrell AS. Visible blue light inhibits infection and replication of SARS-CoV-2 at doses that are well-tolerated by human respiratory tissue. Sci Rep. 2021 Oct 18;11(1):20595. doi: 10.1038/s41598-021-99917-2.
PubMed 34663881Stockslager MA, Kocher JF, Arwood L, Stasko N, McDonald RA, Tapsak MA, Emerson D. Efficacy and hazards of 425 nm oral cavity light dosing to inactivate SARS-CoV-2. J Dent. 2022 Aug;123:104203. doi: 10.1016/j.jdent.2022.104203. Epub 2022 Jun 17.
PubMed 35724941Kuster SP, Shah PS, Coleman BL, Lam PP, Tong A, Wormsbecker A, McGeer A. Incidence of influenza in healthy adults and healthcare workers: a systematic review and meta-analysis. PLoS One. 2011;6(10):e26239. doi: 10.1371/journal.pone.0026239. Epub 2011 Oct 18.
PubMed 22028840Demmler-Harrison GJ. Healthcare-Associated Viral Infections: Considerations for Nosocomial Transmission and Infection Control. Healthcare-Associated Infections in Children. 2018;229-257. Published 2018 Jul 16. doi:10.1007/978-3-319-98122-2_14
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections
- ClinicalTrials.gov ID
- NCT07610967
- Acronym / sponsor ID
- LIGHT / MOFMC.2026.0032
- Conditions
- COVID-19 Respiratory Infection, Influenza
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 130 participants (estimated)
- Lead sponsor
- David MossUS federal agency
- Study start
- 1 Oct 2026 (actual)
- Primary completion
- Jun 2028 (estimated)
- Study completion
- Jun 2028 (estimated)
- First posted
- 28 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of trial is to determine if daily usage of a photobiomodulation device will decrease the incidence of upper respiratory tract infections (URI) due to COVID, influenza or other viruses.The RD-X10 device is handheld, can be self-administered, and has been shown to be safe in invivo studies.
Detailed description
Methods: Subjects 18 years and older working at a DoD medical facility and VA medical facility will be randomized into Active Treatment (Emit Bio ) and sham (inactive device). Basic demographic information will be obtained. Subjects will use the device at home every other day for 5 minutes. Baseline viral upper respiratory PCR panel will be obtained to ensure pre-existing infections are not counted. At first sign of upper respiratory infection symptoms, subjects will contact research personnel and have viral respiratory PCR panel obtained. Research coordinators will also contact subjects every two weeks to ask if they are experiencing or have experienced any upper respiratory symptoms or if they have experienced any side effects of treatment. Subjects reporting any current symptoms or symptoms in the prior 2 weeks will have upper respiratory PCR panel obtained. Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess secondary outcomes including duration of symptoms, missed days of work, outpatient medical visits, ED visits, hospitalizations, medication prescriptions for respiratory illness and over the counter treatments.
Screening visit (Approx 30 min):
- Obtain and document signed Informed Consent document and HIPAA Authorization
- Verify subject eligibility based on inclusion/exclusion criteria (research coordinators may use the electronic medical record to verify inclusion/exclusion)
- Record all medications the subject is taking
- Collect demographic information to include phone number, email address, DoD ID, age, race, ethnicity, sex, whether they directly care for patients, what department they work in, any therapies regularly used to prevent URI (ie zinc, mouth washes, supplements), and immunocompromised state or medications that may suppress the immune system, weight (pounds), height (inches), and BMI
Randomization:
Subjects will be randomized using block randomization (blocks of 6) into one of two research treatment groups, with approximately 50 subjects in each arm for a total of 100 subjects. The study staff assigning subjects to their group will be unblinded to the groups, but patients, investigators, and study staff conducting screening and gathering data will be blinded. The unique study code will be assigned in sequential order beginning with 001.
Group 1: Active RD-X19 every other day for 3 months Group 2: Sham RD-X19 every other day for 3 months
Visit 1 (week 0) (may be same day as screening visit) (approx. 30 minutes):
- Subject will be given the RD-X19 device and shown how to use the device
- Subjects will be instructed to use the device for 5 minutes every other day
- Subject will be given "Instructions for Treatment" handout
- Obtain a baseline PCR panel using a nasal swab
Visits 2-7 (weeks 2-12) (approx. 30 min) can be performed virtually or in person
- Subjects will be asked if they have experienced any upper respiratory symptoms in the last 2 weeks, this may include cough, congestion, sore throat, fatigue, runny nose, sinus pain or pressure, fever (subjective or Temp >100 F), sneezing.
- Subjects experiencing any of the above symptoms will be tested for URI causing viruses using PCR based testing.
- Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess secondary outcomes including duration of symptoms, missed days of work, outpatient medical visits, ED visits, hospitalizations, medication prescriptions for respiratory illness and over the counter treatments. They will also be assessed daily using the WURSS 24 (Wisconsin Upper Respiratory Symptom Survey) daily symptom report until they report a score of 0 for question 1 (How sick do you feel today?)
- Subjects who have not experienced any URI symptoms will be assessed for adherence to RDX19 over the previous 2 weeks and encouraged to continue using the device. They will also be asked if they are experiencing any side effects of the treatment such as throat or mouth irritation, sores in the mouth or on the lips or any other perceived side effects.
- At the end of each study visit, subjects will be asked if the device was used as directed.
Visit 7
-During the subjects final visit, they will be given a questionnaire regarding usage of the device
Device will only be used for a single patient and should be returned to research staff at the end of the study for disposal.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- Group 1: Active RD-X19 every other day for 3 months Group 2: Sham RD-X19 every other day for 3 months
| Arm | Type | Receives |
|---|---|---|
| Group 1: Active RD-X19 every other day for 3 months | Experimental | Device: RD-X19 |
| Group 2: Sham RD-X19 every other day for 3 months | Sham comparator | Device: RD-X19 Sham |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Active Duty and DoD Beneficiaries (i.e. former military, spouse, dependent child) aged 18 years and older who work in the Mike O'Callaghan Military Medical Center at Nellis Air Force Base.
Key exclusion criteria (3 listed)
- Unable to comfortably insert RD-X19 into the mouth and keep in place for 5 minutes
- Plans for head, neck or mouth surgery during the study period
- Plans for major dental procedures (ie implants, wisdom teeth extraction etc) during the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RD-X19* Subject will be given the RD-X19 device and shown how to use the device * Subjects will be instructed to use the device for 5 minutes every other day * Subject will be given "Instructions for Treatment" handout | Device | Group 1: Active RD-X19 every other day for 3 months |
| RD-X19 Sham* Subject will be given the sham RD-X19 device and shown how to use the device * Subjects will be instructed to use the sham device for 5 minutes every other day * Subject will be given "Instructions for Treatment" handout | Device | Group 2: Sham RD-X19 every other day for 3 months |
Primary outcome
difference in PCR confirmed URI (any virus)
Time frame: visit 2 (week 2), visit 3 (week 4), visit 4 (week 6), visit 5 (week 8), visit 6 (week 10), visit 7 (week 12)
difference in PCR confirmed URI (any virus) between active and sham groups between treatment period
11 secondary outcomes
duration of symptoms
Time frame: upper respiratory infection duration, an average of 2 weeks
missed days of work
Time frame: upper respiratory infection duration, an average of 2 weeks
outpatient visits
Time frame: upper respiratory infection duration, an average of 2 weeks
emergency department visits
Time frame: upper respiratory infection duration, an average of 2 weeks
hospitalizations
Time frame: upper respiratory infection duration, an average of 2 weeks
Wisconsin Upper Respiratory Symptom Survey (WURSS 24)
Time frame: upper respiratory infection duration, an average of 2 weeks
number and type of medication prescriptions for respiratory illness
Time frame: upper respiratory infection duration, an average of 2 weeks
number and type of over the counter treatments used
Time frame: upper respiratory infection duration, an average of 2 weeks
differences in incidence of URI amongst different viruses from PCR panels
Time frame: through study duration, an average of 12 weeks
treatment side effects
Time frame: through study duration, an average of 12 weeks
adherence to daily use of RD-X19 device throughout study
Time frame: through study duration, an average of 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
- Background: PubMed 40434113Stasko N, Arwood L, Jandick N, Spragion D, Roberts RC, Setien M, Henson I, Annas A, Fulcher ML, Brotton M, Kummer L, Szaba F, Reagan M, Lanzer K, Cookenham T, Casey S, Kothapalli N, Hart T, Bradrick SS, Emerson D, Cockrell AS, Randell SH, Kocher JF. The pan-variant potential of light: 425 nm light inactivates SARS-CoV-2 variants of concern and non-cytotoxic doses reduce viral titers in human airway epithelial cells. mSphere. 2025 Jun 25;10(6):e0023025. doi: 10.1128/msphere.00230-25. Epub 2025 May 28.
- Background: PubMed 35387539Gibson S, Saunders R, Stasko N, Bickerstaff CB, Oakley J, Osterman M, Torres RT, Kish JK, Feinberg BA, Emerson D. Economic and clinical impact of a novel, light-based, at-home antiviral treatment on mild-to-moderate COVID-19. J Med Econ. 2022 Jan-Dec;25(1):503-514. doi: 10.1080/13696998.2022.2055370.
- Background: PubMed 35137532Stasko N, Cockrell AS, Kocher JF, Henson I, Emerson D, Wang Y, Smith JR, Henderson NH, Wood H, Bradrick SS, Jones T, Santander J, McNeil JG. A randomized, controlled, feasibility study of RD-X19 in subjects with mild-to-moderate COVID-19 in the outpatient setting. Clin Transl Sci. 2022 May;15(5):1291-1303. doi: 10.1111/cts.13249. Epub 2022 Feb 27.
- Background: PubMed 33619888Zupin L, Gratton R, Fontana F, Clemente L, Pascolo L, Ruscio M, Crovella S. Blue photobiomodulation LED therapy impacts SARS-CoV-2 by limiting its replication in Vero cells. J Biophotonics. 2021 Apr;14(4):e202000496. doi: 10.1002/jbio.202000496. Epub 2021 Mar 1.
- Background: PubMed 34663881Stasko N, Kocher JF, Annas A, Henson I, Seitz TS, Miller JM, Arwood L, Roberts RC, Womble TM, Keller EG, Emerson S, Bergmann M, Sheesley ANY, Strong RJ, Hurst BL, Emerson D, Tarbet EB, Bradrick SS, Cockrell AS. Visible blue light inhibits infection and replication of SARS-CoV-2 at doses that are well-tolerated by human respiratory tissue. Sci Rep. 2021 Oct 18;11(1):20595. doi: 10.1038/s41598-021-99917-2.
- Background: PubMed 35724941Stockslager MA, Kocher JF, Arwood L, Stasko N, McDonald RA, Tapsak MA, Emerson D. Efficacy and hazards of 425 nm oral cavity light dosing to inactivate SARS-CoV-2. J Dent. 2022 Aug;123:104203. doi: 10.1016/j.jdent.2022.104203. Epub 2022 Jun 17.
- Background: PubMed 22028840Kuster SP, Shah PS, Coleman BL, Lam PP, Tong A, Wormsbecker A, McGeer A. Incidence of influenza in healthy adults and healthcare workers: a systematic review and meta-analysis. PLoS One. 2011;6(10):e26239. doi: 10.1371/journal.pone.0026239. Epub 2011 Oct 18.
- BackgroundDemmler-Harrison GJ. Healthcare-Associated Viral Infections: Considerations for Nosocomial Transmission and Infection Control. Healthcare-Associated Infections in Children. 2018;229-257. Published 2018 Jul 16. doi:10.1007/978-3-319-98122-2_14
- Individual participant dataSharing planned: Yes. Demographic and clinical data will be acquired from participants. All data will be de-identified prior to receipt by the repository, but the information needed to generate a global unique identifier for the NLM Data Archive (NDA) (clinicaltrials.gov) will be collected for each subject. Sufficient data from this project will be preserved to enable sharing via NDA data of sufficient quality to validate and replicate research findings described in the Aims. NLM requires data measured from human subjects to be shared using the NDA. Demographic data, clinical data, data collection tools and study protocols will be made available in the NDA.
Related trials for COVID-19 Respiratory Infection
RecruitingPhase 3
A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease
SARS-CoV-2
RecruitingObservational study
Viral Infections in Healthy and Immunocompromised Hosts
Anogenital Herpes, COVID-19
Active, not recruiting
Lupus Education Alliance Program
Systemic Lupus Erythematosus, COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
RecruitingPhase 2
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
COVID 19, Influenza
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing RD-X19 in people with COVID-19 Respiratory Infection and Influenza, run by David Moss at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sandra Huffman (7026533583, Sandra.g.huffman.ctr@health.mil), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
difference in PCR confirmed URI (any virus) (time frame: visit 2 (week 2), visit 3 (week 4), visit 4 (week 6), visit 5 (week 8), visit 6 (week 10), visit 7 (week 12)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07610967, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.